PDI guided lower for the third quarter and full year, but CEO Nancy Lurker, says now is the time for investors to look at the company as it just made its first acquisition in the molecular diagnostic space, which has the potential for more growth and higher margins than PDI’s traditional core business and she is bullish on where the new vertical will take the company. Lurker believes the diagnostic business is indicative of what we see happening in healthcare overall with the explosion of personalized healthcare and genomics. Earlier diagnosis of disease will ultimately save the healthcare system more money and impact patient care more positively.

More from Video

Video: Here Is Why Carvana Isn't Worried About Amazon

Video: Here Is Why Carvana Isn't Worried About Amazon

Video: What Oprah's Content Partnership With Apple Means for the Rest of Tech

Video: What Oprah's Content Partnership With Apple Means for the Rest of Tech

REPLAY: Jim Cramer on the Markets, Oil, Starbucks, Tesla, Okta and Red Hat

REPLAY: Jim Cramer on the Markets, Oil, Starbucks, Tesla, Okta and Red Hat

Flashback Friday: The Market Movers

Flashback Friday: The Market Movers

This Could Be the Summer of Hard Seltzer

This Could Be the Summer of Hard Seltzer